Event Registration
September 23, 2025, 4:30 PM CEST | 10:30 AM ET (New York)
(Convert this to your time zone)
With increasing regulatory scrutiny and ethical concerns surrounding non-human primate (NHP) usage, JAX’s humanized mouse models provide a scientifically superior and cost-effective alternative, redefining preclinical antibody drug development. Attendees will learn how these models better recapitulate human physiology, the FcRn IgG recycling system, and functional human immune cell effectors, making them ideal for efficacy, safety, and PK studies.
In this webinar, we will explore:
This virtual event is complimentary.
No fees will be charged for registering.
|
Overview of Regulatory and Scientific Drivers and Introduction Phil Gaskin, Ph.D. Business Development Director The Jackson Laboratory |
|
HuPK Platform: Modeling Human FcRn for Better PK Predictions Adriano Flora, Ph.D. Business Development Director The Jackson Laboratory |
|
Next-Gen Immune-Humanized Models for Antibody Drug Development Brian Soper, Ph.D. Senior Scientific Engagement Manager The Jackson Laboratory |
|
Novel In Vitro and In Vivo Strategies for the Evaluation of Antibody-Drug Conjugates for Oncology Lenka Sadilkova, Ph.D. Director Non-clinical Projects Mablink Bioscience - Eli Lilly |
|
Presentation Title 04 Presenter Name 04 Presenter Title 04 Presenter Company 04 |
